Overview

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Fibromyalgics frequently report sleep disturbances, in particular poor and unrefreshing sleep. Additionally, studies have reported that sleep problems, pain and mood disturbances are associated in patients with fibromyalgia. By improving the quality of sleep, complaints of poor and unrefreshing sleep, fatigue, pain, which are among the main components of this chronic pain disorder may be improved.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
SR 46349B